Mobile Ultra: Advancing Digital Investigations in the Age of Evolving Technology
A New SaaS Solution for Quickly Extracting and Sophisticatedly Managing Large Volumes of Data
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, announced today the release of Mobile Ultra, for mobile device investigations to the private sector. An all-in-one application, Mobile Ultra surfaces facts quickly and accelerates the collection, extractions and reporting process during corporate investigations.
In a fast-paced global economy, corporations, law firms and service providers require innovative, fast and easy approaches for collecting data from mobile devices while keeping pace with technological advancements. Mobile Ultra provides answers to the time-sensitive, critical challenges that corporate investigators often encounter with mobile devices, including the need to quickly find evidence and identify potential missing critical data, all while ensuring that the data is defensible and court-ready.
Mobile Ultra offers a user-friendly interface that seamlessly combines the best features of collection, analysis and review tools, streamlining investigative workflows. It enables investigators to decode and parse data from the widest array of Apple and Android software and devices, enabling industry-leading data analysis. The solution offers full file system extractions enabling comprehensive analysis of the information residing on a mobile device. Additionally, Mobile Ultra provides access to data from more than 50 cloud sources, short-lived messages, third-party chat applications and deleted content, enhancing the probability of discovering crucial evidence.
“Mobile Ultra continues to lead the industry for e-Discovery, corporate investigations and incident response by surpassing previous limitations and providing greater access to comprehensive and accurate data that is fully defensible,” said Ken Basore, General Manager, Cellebrite Enterprise Solutions. “The industry is facing a myriad of challenges including evolving devices and apps, increasing data volumes and deleted data. We’re proud to say Mobile Ultra is the all-in-one solution to address these complex problems.”
In an era where digital investigations play a pivotal role in addressing costly, time-consuming litigation that can impact the business, Mobile Ultra aims to equip investigative professionals with the necessary tools to navigate this evolving landscape effectively. It ensures examiners have the capability to quickly and efficiently uncover all pertinent data, maintaining the highest standards of accuracy and integrity.
To find out more about how Mobile Ultra can advance your investigations, visit our Mobile Ultra webpage.
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes.
Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.
About Cellebrite Enterprise Solutions
In a world that’s evolving rapidly, Cellebrite Enterprise Solutions looks beyond the horizon to design solutions to keep data within reach, transform it and reveal important insights to protect your business and employees. From headquarters to home office, eDiscovery professionals and corporate investigators can access endpoints anywhere with Cellebrite’s enterprise solution offerings.
Sr. Director of Corporate Communications + Content Operations
VP, Investor Relations
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Jotul AS announces fixed income investor meetings to evaluate a NOK 600 million senior secured floating rate bond issue7.12.2023 07:45:00 CET | Press release
Jøtul AS (“Jøtul” or the "Company") has mandated Pareto Securities AB to arrange a series of fixed income investor meetings commencing on 8 December 2023. Subject to, inter alia, market conditions, a 3-year senior secured floating rate bond issue in an initial amount of NOK 600 million under a framework of NOK 900 million may follow (the "Bond Issue"). The proceeds from the contemplated Bond Issue will be used to finance, inter alia, the redemption of the Company's outstanding 2021/2024 bond loan (ISIN NO0011104069) including accrued and unpaid interest, refinance other existing debt, and to finance transaction costs and general corporate purposes. Jøtul also provides certain financial updates relating to the full year figures for 2023 and 2024. The Company expects to post net revenue and adjusted EBITDA of NOK 1,585-1,625 million and NOK 250-270 million respectively in 2023, whereas cash on balance as per year-end is expected to stand at NOK 70-100 million. For the full year of 2024,
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant7.12.2023 07:35:00 CET | Press release
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd aloneFirst global Phase 3 study to report positive results with an anti-CD38 therapy in combination with VRd in transplant-ineligible patients, reinforcing the potential for Sarclisa as a best-in-class medicineStudy results will be submitted for presentation at an upcoming medical meeting and form the basis of a future regulatory submission PARIS, December 7, 2023. The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free surviva
Avance Gas Holding Ltd: Ex Dividend USD 0.50 today7.12.2023 07:01:00 CET | Press release
Hamilton, Bermuda, December 7, 2023 The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 0.50 as of today relating to the dividend for the third quarter of 2023. The dividend will be paid on December 15, 2023. For further information, please contact: Randi Navdal Bekkelund - Chief Financial Officer Tel: +47 23 11 40 00 Email: IR@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs) and operates a fleet of fourteen modern ships including two dual fuel LPG newbuildings for delivery in early 2024 as well as four medium sized gas/ammonia carriers due for delivery in 2025 and 2026. For more information about Avance Gas, please visit www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook7.12.2023 07:00:00 CET | Press release
PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results. Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and road
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC7.12.2023 07:00:00 CET | Press release
New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade. The target FDA PDUFA date under priority review is June 10, 2024. The European Medicines Agency (EMA) has also validated Ipsen’s Marketing Authorization Applica